MSRV Retrovirus, phase 2

Fred1208 · Post by **Fred1208** » Mon Feb 25, 2019 3:42 pm

Here is a full presentation of the Company (February 2019) ;

http://www.geneuro.com/data/documents/2 ... -Pres1.pdf

Regarding EDDS comparisons, it should come in Phase III.
..
Geneuro is currently in discussion to find a new financial partner.

frodo · Post by **frodo** » Sat Mar 02, 2019 3:18 am

Thanks. Quite interesting.

I have also found a review about the trial in the web. It seems that the results are very promising:

https://multiplesclerosisnewstoday.com/ ... shrinkage/

Fred1208 · Post by **Fred1208** » Tue Mar 12, 2019 11:01 am

Excellent results for extension study ANGEL-MS given today!

http://www.geneuro.com/data/documents/A ... tation.pdf

Fred1208 · Post by **Fred1208** » Sat Mar 23, 2019 10:41 am

GeNeuro presentations

February and March

http://www.geneuro.com/en/investors/doc ... tations-en

Fred1208 · Post by **Fred1208** » Tue Jul 02, 2019 8:17 am

Geneuro presentation, June 2019:

https://www.geneuro.com/data/documents/ ... tation.pdf

PNAS ARTICLE:

https://www.pnas.org/content/early/2019 ... 1901283116

zen2010 · Post by **zen2010** » Tue Jul 02, 2019 9:56 am

Hello,

1)I can read (Page 20) : "3.8% of patients with 12-week confirmed worsening in neurological disability from CHANGE-MS baseline to week 48 ANGEL (at 18mg/Kg)"
=>So it's not working for everyone

2)I can also read (Page 21): Adverse Events for 44.2% of patients. That's HUGE!

Point "1)" seems to show a positive correlation between the % of patients and the dosage. So I guess higher dosage will lead to almost 0% worsening.
However, point "2)" is really disturbing!

You said (Page 3 of this thread) this product was a revolution.

For me, a revolution means 100% safe.
Don't you agree?

frodo · Post by **frodo** » Thu Jul 04, 2019 4:00 am

zen2010 wrote: ↑
Tue Jul 02, 2019 9:56 am
For me, a revolution means 100% safe.
Don't you agree?

Unfortunately, in MS a revolution is anything that can delay the disease. What we have now, only prevents inflammatory attacks, with no effects in the long term.

Besides it is not clear what adverse event means. It could be just a headache.

But the most interesting part is not if this drug works, but the things we are learning. Now it seems pretty clear that HERVs are the cause of microglial activation (the root cause of progression) and just a couple of years ago this was unknown.

zen2010 · Post by **zen2010** » Tue Jul 16, 2019 6:36 am

frodo wrote: ↑
Thu Jul 04, 2019 4:00 am
Now it seems pretty clear that HERVs are the cause of microglial activation (the root cause of progression) and just a couple of years ago this was unknown.

Hi Frodo,

I trully hope, more than anybody, that Geneuro will provide something efficient to us.

BUT, there is a HUGE difference between what I hope and what I can see.

Indeed, on a hand:
-As you said: "it seems pretty clear that HERVs are the cause of microglial activation (the root cause of progression)"
-Studies from Geneuro showed their product was working
-Information above was shared in important media like "medicalresearch.com" or "pnas.org"

on the other hand:
-There isn't a single company like Biogen or Roche, which is interested in Geneuro's product
-The companies I mentioned above have departments dedicated to find business opportunities
-It's been more than one year since Geneuro is trying to find a partnership to continue its development...

So, to sum up:
Some MSers behind their computers (driven by hope)talk about revolution, but the market doesn't give a dam about Geneuro.

So pls allow me to have some doubts here...

frodo · Post by **frodo** » Wed Jul 31, 2019 11:49 pm

Maybe you are right ... There was a lot of wishful thinking from my side. But some day something has to appear, and the evolution of the discovery cannot be very different from this one.

Fred1208 · Post by **Fred1208** » Thu Sep 12, 2019 1:10 am

Why did I write revolution ?

Because for the first time, i seems tht someone found the trigger explanation for the desease.
For the first time, this product would BLOCK the degeneration process, leading to disability.

WITHOUT side effects, it doesn't modify IN ANY WAY immunity system.
"An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment." (wiki)

The discussion to find a patner in order to get a partnersship is currently in progress.
This kind of discussion is ALWAYS long, please be patient.

Results of phase II will be presented at ECTRIMS in Stckholm tomorrow.

Fred1208 · Post by **Fred1208** » Sat Sep 14, 2019 7:55 am

ECTRIMS

PDF poster: http://www.geneuro.ch/data/news/P1379-Ectrims-2019.pdf

Fred1208 · Post by **Fred1208** » Sat Oct 03, 2020 2:42 am

A revolution could come very soon.

Please stay tuned..

Fred1208 · Post by **Fred1208** » Mon Oct 05, 2020 12:47 am

Channel link :

https://www.youtube.com/channel/UCODwH_ ... lVhGzmw0pA

Fred1208 · Post by **Fred1208** » Mon Oct 05, 2020 4:18 am

Please subssribe to receive news ..

Fred1208 · Post by **Fred1208** » Mon Oct 05, 2020 4:34 am

To Zen2010 :

You wrote : "-There isn't a single company like Biogen or Roche, which is interested in Geneuro's product"

Are you sure?

Please wait.

Until the end of the Sweden trial (end of 2021)

You could be amazed

This Is MS Multiple Sclerosis Knowledge & Support Community

MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2

Re: MSRV Retrovirus, phase 2